Relevant bibliographies by topics / Prurits – Psychologie / Journal articles
To see the other types of publications on this topic, follow the link: Prurits – Psychologie.

Journal articles on the topic 'Prurits – Psychologie'

Author: Grafiati
Published: 11 January 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 33 journal articles for your research on the topic 'Prurits – Psychologie.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Stumpf, Astrid, Gudrun Schneider, and Sonja Ständer. "Psychosomatic and psychiatric disorders and psychologic factors in pruritus." Clinics in Dermatology 36, no. 6 (November 2018): 704–8. http://dx.doi.org/10.1016/j.clindermatol.2018.08.015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Saurat, Jean-Hilaire, and Michèle Saurat. "Prurit et douleur." Revue française de psychosomatique 15, no. 1 (1999): 213. http://dx.doi.org/10.3917/rfps.015.0213.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jaeger, Philippe. "Prurits, irritations chroniques de la peau et urticaire." Revue française de psychosomatique 29, no. 1 (2006): 51. http://dx.doi.org/10.3917/rfps.029.0051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Härtl, Kristin, Marianne Müller, Florian Bergauer, and Klaus Friese. "Chronische Schmerzen bei Vulvodynie und Pruritus vulvae." Psychotherapeut 55, no. 3 (April 16, 2010): 241–46. http://dx.doi.org/10.1007/s00278-010-0741-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gupta, M. A., A. K. Gupta, N. J. Schork, and C. N. Ellis. "Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria." Psychosomatic Medicine 56, no. 1 (January 1994): 36–40. http://dx.doi.org/10.1097/00006842-199401000-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Shaw, Richard J., Shaili Dayal, Julie Good, Anna L. Bruckner, and Shashank V. Joshi. "Psychiatric Medications for the Treatment of Pruritus." Psychosomatic Medicine 69, no. 9 (November 2007): 970–78. http://dx.doi.org/10.1097/psy.0b013e3181572799.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Habib, Suzanne, and Shirley Morrissey. "Stress Management for Atopic Dermatitis." Behaviour Change 16, no. 4 (December 1, 1999): 226–36. http://dx.doi.org/10.1375/bech.16.4.226.

Full text
Abstract:
AbstractAtopic dermatitis (AD) is a chronic, debilitating skin disorder that accounts for up to 20% of dermatological diagnoses. A 6-week psychoeducational stress management program was developed, implemented, and evaluated as an adjunctive treatment for AD. The participants (n = 17) were randomly assigned to a treatment or waiting-list control group. Participants in both the intervention and waiting-list control groups were assessed for dermatitis severity by a blind rater both pre and posttreatment and at a follow-up conducted 8 weeks after the conclusion of the program. At posttest the intervention group had significantly reduced pruritus and global severity of atopic dermatitis, and reduced levels of social anxiety and private self-consciousness. At an 8-week follow-up, pruritus was entirely absent and global severity was continuing to decrease, as were levels of social anxiety and private self-consciousness. The psychoeducational stress-management program provided a short effective treatment that resulted in reduction of symptoms and provided long-term management strategies to sufferers of atopic dermatitis.
APA, Harvard, Vancouver, ISO, and other styles
8

Laurent, Annie, Jacques Boucharlat, Jean-Luc Bosson, Andrew Derry, and Roger Imbert. "Psychological Assessment of Patients with Idiopathic Pruritus ani." Psychotherapy and Psychosomatics 66, no. 3 (1997): 163–66. http://dx.doi.org/10.1159/000289128.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Biondi, M., T. Arcangeli, and R. M. Petrucci. "Paroxetine in a Case of Psychogenic Pruritus and Neurotic Excoriations." Psychotherapy and Psychosomatics 69, no. 3 (2000): 165–66. http://dx.doi.org/10.1159/000012386.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Stein, Traci R., Nomita Sonty, and John M. Saroyan. "“Scratching” beneath the surface: An integrative psychosocial approach to pediatric pruritus and pain." Clinical Child Psychology and Psychiatry 17, no. 1 (June 13, 2011): 33–47. http://dx.doi.org/10.1177/1359104511406969.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Ríos-Burgueño, Efrén Rafael, Cynthia Marina Urías-Barreras, Melissa Martínez-Félix, David de Jesús Morán-Pórtela, Saúl Armando Beltrán-Ontiveros, and Jesús Salvador Velarde-Félix. "Adenocarcinoma pancreático de glándulas espumosas, entidad infrecuente que simula lesión benigna: un reto diagnóstico." REVMEDUAS 12 (September 1, 2022): 69–72. http://dx.doi.org/10.28960/revmeduas.2007-8013.v12.se.009.

Full text
Abstract:
Resumen El adenocarcinoma pancreático de glándulas espumosas (APGE) es una de las neoplasias de páncreas pocos fre-cuentes con características similares a tumores benignos, este tipo de diagnóstico representa un verdadero reto al médico anatomopatólogo debido a que la lesiones suelen confundirse con alteraciones benignas principalmente por la presencia de células espumosas de citoplasma amplio vacuolado y núcleo pequeño que parecen macrófagos es-pumosos. Se presenta un caso clínico de paciente femenino de 66 años con APGE presentando síntomas como aco-lia, coluria, ictericia conjuntival, prurito, dolor en hipocondrio derecho constante de leve a moderada intensidad, anorexia, náuseas y vómitos, con pérdida de peso de 6 kg en dos meses. Palabras clave: APGE, cáncer de páncreas, diagnóstico
APA, Harvard, Vancouver, ISO, and other styles
12

Hazra, Pallavi, Shyamal Kumar Mukherjee, Subhasish Ganguly, Aniket Singha Roy, Souvik Dutta, Satarupa Sadhukhan, Munmun Koley, and Subhranil Saha. "A Comparative Study of 50-Millesimal Potencies and Centesimal Potencies in the Treatment of Tinea Corporis: An Open, Randomised, Pilot Trial." Homœopathic Links 34, no. 04 (December 2021): 267–77. http://dx.doi.org/10.1055/s-0041-1734025.

Full text
Abstract:
Abstract Introduction Standard management of dermatophytosis involves the use of topical antifungals in limited disease and oral therapy for more extensive cases. Despite the evidences favouring homeopathy in tinea corporis (TC) is inadequate, patients are increasingly opting for it. This trial attempts to assess the feasibility of a trial evaluating individualised homeopathic (IH) medicines in centesimal and 50-millesimal potencies in treating TC. Methods An open, randomised, pilot feasibility trial was conducted at the dermatology outpatient of D. N. De Homoeopathic Medical College and Hospital, West Bengal, India. Patients were randomised to receive IH medicines in either centesimal potencies (n = 30) or in 50-millesimal potencies (n = 30). Primary outcome measure was intensity of pruritus on a 0 to 10 numeric rating scale; secondary outcomes were Skindex-29 and dermatology life quality index questionnaires—all measured at baseline, and after 6 and 12 weeks of intervention. Group differences were calculated on intention-to-treat (ITT) sample as well as following per protocol (PP) analysis. Results Recruitment and attrition rates were 69 and 16.7% respectively. Both ITT and PP analysis revealed that intra-group changes in both the primary and secondary outcomes to be statistically significant in both the groups (all p < 0.05, one-way repeated measure analysis of variance). There were no significant group differences over 6 and 12 weeks (all p > 0.05, unpaired t-tests); thus, indicating similar pattern of improvement in both the groups. Most frequently used medicines were Natrum sulphuricum (28.3%), Natrum muriaticum (25%), Sulphur (8.3%) and Bacillinum (6.7%). No harms, unintended effects, homeopathic aggravations or any serious adverse events were reported from either group. Conclusion An adequately powered trial exploring effectiveness of both scales in TC appeared to be feasible in future. Though the sample size was too small to arrive at any definite conclusion, both centesimal and 50-millesimal potencies of IH medicines appeared to be equally useful in improving pruritus intensity and quality of life in patients suffering from TC.
APA, Harvard, Vancouver, ISO, and other styles
13

Rucklidge, Julia J., and Douglas Saunders. "The efficacy of hypnosis in the treatment of pruritus in people with hiv/aids: A time-series analysis." International Journal of Clinical and Experimental Hypnosis 50, no. 2 (April 2002): 149–69. http://dx.doi.org/10.1080/00207140208410096.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Sabalingam, Sriaandhal, and Malitha Aravinda Siriwardhene. "A systematic review of the effects of Curcuma longa topical formulations on wound healing." Asian Journal of Pharmaceutical Research and Development 10, no. 6 (December 14, 2022): 71–76. http://dx.doi.org/10.22270/ajprd.v10i6.1192.

Full text
Abstract:
Topical herbal formulations are gaining more attention in wound healing due to their safety and efficacy. This is a systematic review of the effects of Curcuma longatopical formulations on wound healing. C. longa is a traditional medicinal plant used due to its antimicrobial, antioxidant, anti-inflammatory, and wound healing properties. Studies carried outas randomized control trials and clinical trials were included for the analysis of this review. Searches were conducted in PubMed, Scopus, Cochrane Central Register of Controlled Trials, and Google scholar (up to March 2022) with 04 studies meeting the inclusion criteria. All randomized control trials and clinical trials have shown a significant improvement in wound healing. The topical formulations containing C. longa as an ingredient have reportedly improved wound healing in cases of eczema, radiodermatitis, acne vulgaris, atopic dermatitis, ichthyosis vulgaris, senile pruritis, and xerotic skin conditions, according to the studies covered in this review.This review identified some evidence that C. longa extract has good effects for wound healing, in accordance with its use in traditional medicine. To evaluate the impact of C. longa on wound healing, including complications, larger, well-designed randomized control trials are required.
APA, Harvard, Vancouver, ISO, and other styles
15

Wenhao, Song, Wang Quanwei, Fu Wenwen, Zhang Ce, and Wang Tian. "The Role of Ginsenosides in Myocardial Ischemic Injury-A Systematic Review." Asian Journal of Pharmaceutical Research and Development 10, no. 6 (December 14, 2022): 61–70. http://dx.doi.org/10.22270/ajprd.v10i6.1191.

Full text
Abstract:
Topical herbal formulations are gaining more attention in wound healing due to their safety and efficacy. This is a systematic review of the effects of Curcuma longatopical formulations on wound healing. C. longa is a traditional medicinal plant used due to its antimicrobial, antioxidant, anti-inflammatory, and wound healing properties. Studies carried outas randomized control trials and clinical trials were included for the analysis of this review. Searches were conducted in PubMed, Scopus, Cochrane Central Register of Controlled Trials, and Google scholar (up to March 2022) with 04 studies meeting the inclusion criteria. All randomized control trials and clinical trials have shown a significant improvement in wound healing. The topical formulations containing C. longa as an ingredient have reportedly improved wound healing in cases of eczema, radiodermatitis, acne vulgaris, atopic dermatitis, ichthyosis vulgaris, senile pruritis, and xerotic skin conditions, according to the studies covered in this review.This review identified some evidence that C. longa extract has good effects for wound healing, in accordance with its use in traditional medicine. To evaluate the impact of C. longa on wound healing, including complications, larger, well-designed randomized control trials are required.
APA, Harvard, Vancouver, ISO, and other styles
16

Musselman, Meghan, Justin Faden, and Leslie Citrome. "Asenapine: an atypical antipsychotic with atypical formulations." Therapeutic Advances in Psychopharmacology 11 (January 2021): 204512532110352. http://dx.doi.org/10.1177/20451253211035269.

Full text
Abstract:
Asenapine is a second-generation (atypical) antipsychotic medication not available in a pill that can be swallowed; rather, it is commercialized in sublingual and transdermal formulations. This is a consequence of extensive first-pass metabolism if ingested. The sublingual formulation is approved in many jurisdictions for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder and is available generically. The efficacy profile is well characterized in a number of clinical trials, including an off-label use for the management of agitation. Obstacles to its use include food and drink restrictions, twice-daily dosing and adverse effects such as dysgeusia (distorted, altered, or unpleasant taste) and oral hypoesthesia (numbness). Transdermal asenapine was approved by the US Food and Drug Administration in 2019 for the treatment of schizophrenia in adults. Efficacy was established in a registrational study examining acutely ill inpatients with schizophrenia. The patch needs to changed once daily. Obstacles to its use include the potential for skin reactions such as erythema and pruritis, and being a branded product, it is more costly than other options. This is a narrative review of the chemistry and pharmacokinetics/pharmacodynamics of asenapine, as well as summarizing the efficacy and tolerability of both sublingual and transdermal asenapine, and its possible place in treatment.
APA, Harvard, Vancouver, ISO, and other styles
17

Lu, Li, Han Gao, Weili Yusufu, Baihitiyaer Yimamu, Maijimi Simayi, Xiangdong Sun, Weilong Qiao, Xiaoxue Wang, Abulimiti Abudouhalike, and Donglin Ren. "Associated Behavioral Factors and Prevalence of the Common Anorectal Disease Among Uyghur Male Adults of China: A Population-Based Crosssectional Study." American Journal of Health Behavior 47, no. 2 (April 30, 2023): 237–52. http://dx.doi.org/10.5993/ajhb.47.2.4.

Full text
Abstract:
Objectives: We investigated the behavioral associated factors and prevalence of common anorectal disease (hemorrhoids, perianal pruritus, anal fistula, and others) among Uyghur male adults in southern Xinjiang. Methods: We conducted a cross-sectional study with a random sampling method from December 2020 to March 2021. Uyghur males aged 18 years and older were selected from Kashgar Prefecture in Xinjiang. The prevalence was evaluated by a bilingual questionnaire (including socio- demographic information, dietary habit, lifestyle, and behavioral habits) and anorectal examinations. The chi-square test was used for categorical variables. Logistic regression analysis was used to identify potential associated factors.Results: A total of 402 Uygur males aged ≥ 18 years were included in the final analysis. Of those, 192 (47.8%) participants were identified with common anorectal disease (CAD). Older age, lower education attainment, being a farmer, having lower personal annual income, having a high level of alcohol consumption, performing less anus-rinsing after defecation, and having less pubic hair removal were significantly associated with CAD. Conclusions: Common anorectal disease is a significant public health concern for the Uygur male population. Anus-rinsing after defecation and pubic hair removal are ethnic-specific behaviors among Uygur and could be preventive strategies for CAD.
APA, Harvard, Vancouver, ISO, and other styles
18

Curtis, L., B. Hallahan, and F. Byrne. "A clozapine-induced hypersensitivity reaction." Irish Journal of Psychological Medicine 37, no. 2 (October 17, 2017): 122–25. http://dx.doi.org/10.1017/ipm.2017.45.

Full text
Abstract:
A 57-year-old female patient with a diagnosis of schizo-affective disorder since 1986 was commenced on clozapine due to persistent positive and negative psychotic symptoms in September 2014. After commencement of clozapine she was delusion free and demonstrated an improvement in negative symptoms. Three months after commencement of clozapine she developed a hypersensitivity reaction. Her symptoms continued to deteriorate despite being prescribed an anti-histamine. Clozapine was discontinued 6 days after the appearance of a generalised pruritic rash, as it was believed to be the probable cause. There was complete resolution of symptoms 1 week after discontinuation of clozapine. Clozapine was replaced with olanzapine and amisulpride. There has been no similar cutaneous or allergic reactions for the past 30 months.
APA, Harvard, Vancouver, ISO, and other styles
19

Torres-Escobar, Nadxieli Jacqueline, Silvia Annel Prince-Angulo, Felipe De Jesús Peraza-Garay, and Marina Canizales-López. "Eficacia analgésica de ropivacaína al 2% + fentanilo vs ropivacaína al 2% + morfina vía peridural en pacientes con herida contaminada en el pos quirúrgico inmediato." REVMEDUAS 12, no. 3 (September 21, 2022): 167–74. http://dx.doi.org/10.28960/revmeduas.2007-8013.v12.n3.002.

Full text
Abstract:
Objetivo: Determinar que combinación es más eficaz para el control del dolor y el comportamiento hemodinámico en el posoperatorio en pacientes sometidos a lavado de herida quirúrgica contaminada en hemicuerpo inferior. Metodología: Se realizó un ensayo clínico controlado, prospectivo, longitudinal, comparativo, aleatorizado y doble ciego en pacientes adultos con herida contaminada de hemi-cuerpo inferior, se realizaron 2 grupos con un total de 87 pacientes, 40 pacientes con ropivacaína 2% + fentanilo 100mcg (Grupo RF) y 47 pacientes con ropivacaína 2% + morfina 2mg (Grupo RM) por vía peridural. Durante el posquirúrgico se monitorizó la frecuencia cardiaca, presión arterial, frecuencia respiratoria, saturación de oxígeno, la presencia o ausencia de prurito, náusea y/o vómito, escala visual análoga (EVA) a la primera hora, 2 y 4 horas posteriores al aseo quirúrgico. Resultados: De manera respectiva para grupo RF (40) y RM (47), se observó en la evaluación del dolor con la escala EVA, con puntaje de cero en la primera hora el grupo RF 20 (50%) y del RM 47 (100%) p= <0.000. A las 2 horas con puntaje de cero, el grupo RF 6 (15%) y el RM 35 (74.5%) p= <0.000. A las 4 horas en escala cero del grupo RF 4 (10%) y del RM 21 (44.7%) p= <0.000. Conclusiones: El grupo ropivacaína 2% + morfina presentó mejor analgesia que el grupo ropivacaína 2% + fentanilo. Palabras clave: Ropivacaina, Fentanilo, Morfina, peridural, dolor.
APA, Harvard, Vancouver, ISO, and other styles
20

Acharki, Mohamed, Soumaya Jellal, Mouna Salihoun, and Nawal Kabbaj. "Endoscopic Ultrasonography-Guided Biliary Drainage: Experience of a Moroccan Center." Saudi Journal of Medicine 8, no. 08 (August 23, 2023): 457–63. http://dx.doi.org/10.36348/sjm.2023.v08i08.008.

Full text
Abstract:
Background: Endoscopic ultrasound-guided biliary drainage (EUS-BD) is a relatively new therapeutic modality in the arsenal of endoscopists for attaining satisfactory biliary drainage when traditional ERC fails. The aim of our study is to describe the first Moroccan experience with EUS-BD in patients with malignant biliary obstruction after a failed or inaccessible ERCP. Methods: This is a retrospective study conducted at Ibn Sina Hospital, from Mars 2018 to July 2022, which include 27 patients with an inoperable or metastatic malignant biliary obstruction who underwent endoscopic ultrasonography-guided biliary drainage (EUS-BD) in case of endoscopic retrograde cholangiopancreatography (ERCP) failure. Results: From a total of 288 patients with malignant biliary obstruction,27 underwent EUS-BD (9,3%), 15 EUS-guided hepaticogastrostomy (55,5%) and 12 EUS-guided choledocoduodenostomy (44,4%) were performed. The mean age was 62.5 years (age range: 23-74 years), a male predominance of 59% was noted, cholestatic jaundice was present in 100% of patients and associated with pruritus in 92.59% of cases. The mean level of Total Bilirubin was 190 mg/l. The causes of biliary obstruction were: an inoperable pancreatic head mass in 13 patients(48,1%), a cholangiocarcinoma in 7 patients (25.9%), an ampullary mass in 4 patients(14,8%), a gallbladder cancer with hepatic and duodenal invasion in one patient (3,7%), a gastric antropyloric adenocarcinoma with pancreatic head invasion in one patient (3,7%) and Duodenal adenocarcinoma in one patient (3,7%).The leading causes of failed ERCP were secondary to tumor infiltration of the duodenal wall and critical duodenal stenosis in 11 cases (40,7%), in 9 cases due to a difficult cannulation (33.3%) and in 7 cases due to a failure to pass the stricture by ERCP (25.9%). In EUS-HG The technical and the clinical success rates were 86.6% (13/15) and 84.6% (11/13), respectively, the complication rate was 13.3% (2/15) including one case of stent migration complicated with bile leak and one case of cholangitis. In EUS-CD The technical and the clinical success rates were 91.6% (11/12) and 81.8% (9/11)), respectively, the complication rate was 16.6% (2/12) including two cases of cholangitis. The technical and the clinical success rates in all EUS-BD were 85.1% (24/27) and 83.3% (20/24), respectively. The complication rate was 14.8% (4/27). Conclusion: EUS-BD appears to be an effective and safe therapeutic option for biliary decompression in cases where ERCP fails.
APA, Harvard, Vancouver, ISO, and other styles
21

., Naseemullah, Abdul Qayum Khan, Farooq Azam Khan, Shahzad Rashid Awan, and Mehran Khan. "Efficacy of Intramuscular Platelet Rich Plasma Versus Oral Antihistamine In Chronic Urticaria." Pakistan Journal of Medical & Health Sciences 16, no. 10 (October 30, 2022): 390–92. http://dx.doi.org/10.53350/pjmhs221610390.

Full text
Abstract:
Background: Chronic urticaria is defined as a pruritic skin disorder that persists daily or about daily for ˃6 weeks. Chronic urticaria is a common problem in Pakistan. The common treatment method is oral histamine. Currently the important treatment method used is autologous serum therapy. The objective of this study was to determine the efficacy of intramuscular platelet rich plasma versus oral antihistamine in the treatment of chronic urticaria Methodology: This study was randomized controlled clinical trial carried out at the Dermatology Department, Qazi Hussain Ahmad Complex Nowshera and alshifa clinic and skin aesthetic, Nowshera from May 2020 to May 2021. 100 patients were included in this research work. They were randomly divided into two groups of 50 patients each. One group was given autologous serum while the other was given antihistamine. The autologous serum group patients were treated by giving 9 intramuscular injection of autologous serum while the antihistamine group patients were treated with oral antihistamine on routine basis. UAS-7 (Urticaria Activity score-7) was used for measuring the effectiveness of both the treatment methods. Results: At baseline in autologous serum group, the Urticaria activity score was 36.1 (±6.7) while in antihistamine group it was 35.2 (±5.4) respectively. At baseline Urticaria activity score was non-significant (p=0.85). At 4th week the mean Urticaria activity score in autologous serum group and antihistamine group was 18.3(±3.6) and 30.2.1 (±5.1) (p=0.01). At 9th week in autologous serum group, the Urticaria activity score was 11.3 (±6.3) while in antihistamine group it was 22.6 (±4.9). (p=0.04) At 12th week the mean Urticaria activity score in autologous serum group and antihistamine group was 7.1(±5.4) and 20.4 (±7.3) respectively (p=0.01). Conclusion: Our study concludes that autologous serum therapy is more effective as compared to antihistamine in the treatment of chronic urticaria Keywords: Chronic Urticaria; Intramuscular platelet rich plasma; Oral antihistamine
APA, Harvard, Vancouver, ISO, and other styles
22

Wadood, Fazal, Madiha Zafar, Dur I. Shahwar, Umar Iqbal, Shahid Adalat Chaudhry, and Varda Balouch. "A Comparative Study on the Efficacy of Tramadol and Fentanyl Added To Low Dose Bupivacaine in Subarachnoid Block for Caesarean Section." Pakistan Journal of Medical and Health Sciences 16, no. 6 (June 30, 2022): 1080–82. http://dx.doi.org/10.53350/pjmhs221661080.

Full text
Abstract:
Background: A caesarean section is the utmost communal surgical procedure. An adjuvant with a low dose of bupivacaine added to a cesarean section is a better option. Aim of the study: It is planned to study the effect of fentanyl and tramadol added to a low dose of bupivacaine on subarachnoid blockade in caesarean section. Place and duration: In the Anesthesia and Obstetrics and Gynecology department of Khyber Teaching Hospital, Peshawar and Arif Memorial Teaching Hospital, Lahore for six-moths duration from July 2021 to December 2021. Methods: 90 patients were randomized into three groups, 30 pregnant females in each group. Group A received 0.5% bupivacaine 7.5 mg (one and a half ml), 5% dextrose in 0.5 ml water and total of 2 ml, group B 0.5% bupivacaine 5 mg, fentanyl 50 µg, total 2 ml. In group C, 0.5% bupivacaine was used together with 50 mg of tramadol, and a total of 2 ml was used for spinal anesthesia. The height of the sensory block was evaluated by the method of pinprick and the quality of the motor block by the Bromage scale. The effective duration of analgesia was recorded when patients requested the 1st dose of analgesia. The APGAR score was documented at one and five minutes after the baby was born. Results: In group A; mean duration of blockade was 118.50 ± 23.60; It was 168.00 ± 30.21 mints in Group B and 215.00 ± 26.51 mints in C Group, which was significant between the three groups (P = 0.01). The systolic blood pressure has mean change among the three groups after 3, 4, 5, 6, 8, 9, 10, 20 and 30 min was significant after SAB, and the diastolic blood pressure mean change after SAB was significant at 2, 3, 8, 9, 10, 20 minutes and the p-value were 0.021, 0.037, 0.059, 0.032, 0.042, 0.065, respectively. Hypotension developed in 9 cases of A group; 10 patients of B Group and 6 in the C group. There was one case pruritus in group A; group B has 7 patients with itching and no group C has no case of itching. The measurement of VAS after SAB was significant between groups. There was also a significant variance in VLAS among the groups in the first hour (P = 0.00049), the 2nd hr. (P - 0.007), and the 3rd hr. (P = 0.001) after SAB, and the interaction between the groups was significant (P = 0.001). Conclusion: The combination of bupivacaine and tramadol may be a better option as an intrathecal anesthetic compared to 0.5% bupivacaine in 0.5 ml of 5% dextrose or 0.5% bupivacaine in combination with fentanyl. Keywords: SAB, Bupivacaine, Fentanyl and Tramadol
APA, Harvard, Vancouver, ISO, and other styles
23

Conrad, R., F. Geiser, M. Hutmacher, R. Liedtke, G. Haidl, and F. Wermter. "Relationship between anger and pruritus perception in chronic idiopathic urticaria." PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie 57, no. 02 (February 2007). http://dx.doi.org/10.1055/s-2007-970632.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Fawaaz Lateef, Shaikh, and G. S. Ramagopal. "A RARE CASE REPORT ON ROLE OF TOFACITINIB IN TREATMENT OF REFRACTORY HYPERTROPHIC LICHEN PLANUS." INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, March 1, 2023, 20. http://dx.doi.org/10.36106/ijsr/7603953.

Full text
Abstract:
Lichen planus¹ is an Chronic dermatoses with various types of clinical presentations. Hypertrophic² Lichen planus is one type , with severe pruritus³not responding to variety of medications like topical and systemic steroids , immunosuppressive agents. This is a rare case report where refractory Hypertrophic Lichen planus was treated with Tofacitinib with excellent clinical outcome and noticeable improvement in parameters
APA, Harvard, Vancouver, ISO, and other styles
25

Heapy, Connor, Paul Norman, Lisa-Marie Emerson, Ruth Murphy, Susan Bögels, and Andrew R. Thompson. "Is Parental Mindfulness Associated with Quality of Life and Itch Intensity in Children with Psoriasis and Eczema and Well-being in Parents?" Mindfulness, September 4, 2021. http://dx.doi.org/10.1007/s12671-021-01733-2.

Full text
Abstract:
Abstract Objectives Childhood psoriasis and eczema negatively impact the well-being of children and their parents. Identifying variables that protect against, or reduce, the negative impact of these skin conditions could greatly improve the lives of children with these skin conditions and their parents. We therefore aimed to investigate whether higher levels of parental dispositional mindfulness are associated with lower levels of psychological distress and better quality of life in children with psoriasis or eczema and their parents. Methods Children with psoriasis or eczema (n = 180, M age = 10.22, females = 108) and their parents (n = 210, M age = 39.97, females = 183) were recruited from social media and NHS dermatology clinics in the UK. Parents completed questionnaires assessing dispositional mindfulness, parental stress, psychological distress (depression, anxiety, general stress), and quality of life related to their child’s skin condition. Children completed questionnaires assessing quality of life related to their skin condition and pruritus (itch intensity). Results Parental dispositional mindfulness explained significant amounts of variance in parental stress, parent depression, parent anxiety, parent general stress, and both parent and child quality of life. These relationships were not moderated by skin condition. Conclusion Parental dispositional mindfulness is associated with better well-being in parents of children with psoriasis or eczema, and their children. Mindfulness-based interventions for parents may be beneficial for improving well-being in both children with skin conditions and their parents. Trial Registration: https://aspredicted.org/xf429.pdf (see Supplementary Materials A).
APA, Harvard, Vancouver, ISO, and other styles
26

Dröge, Carola, Tobias Götze, Annika Behrendt, Holger Gohlke, and Verena Keitel. "Diagnostic workup of suspected hereditary cholestasis in adults: a case report." Exploration of Digestive Diseases, April 21, 2023, 34–43. http://dx.doi.org/10.37349/edd.2023.00016.

Full text
Abstract:
Hereditary cholestasis comprises a broad spectrum of clinical phenotypes of varying severity. Severe forms such as progressive familial intrahepatic cholestasis (PFIC) mostly affect children with disease onset within their first years. Nevertheless, late-onset PFIC forms are increasingly diagnosed. Most adults present with less severe forms of hereditary cholestasis, often suffering from pruritus, gallstone disease, jaundice, or elevated liver enzymes. To identify the underlying genetic background and to rule out potential differential diagnoses, a broad genetic analysis like whole exome sequencing (WES) is recommended. Knowledge of the affected gene may have an impact not only on patient surveillance due to risk for disease progression or tumor development but also on potential therapeutic strategies. This case of the adult patient illustrates the importance of broad genetic analysis, which brought up the potentially relevant rare multidrug resistance protein 3 (MDR3) missense variant p.(Asn489Tyr) underlying the patient’s clinical phenotype of low phospholipid-associated cholelithiasis (LPAC). Patients with MDR3 disease may have an increased risk for cholangiocarcinoma (CCA) development and therefore need an individualized surveillance strategy. Most MDR3-affected patients benefit from life-long therapy with ursodeoxycholic acid (UDCA), which is well tolerated. Bezafibrate treatment can reduce pruritus, one of the main symptoms affecting the quality of life. Whether the administration of ileal bile acid transporter (IBAT) inhibitors is beneficial in adult patients with MDR3 disease is so far unknown.
APA, Harvard, Vancouver, ISO, and other styles
27

Botello-Villagrana, Fernando, and Daniel Martinez-Ramirez. "Mucuna pruriens as adjunct therapy to levodopa in advanced Parkinson’s disease." Revista Mexicana de Neurociencia 22, no. 5 (October 11, 2021). http://dx.doi.org/10.24875/rmn.21000010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

LaCour. "Parameters of Scratch Pleasurability in the Management of Pruritic Conditions." Cutis 110, no. 2 (August 2022). http://dx.doi.org/10.12788/cutis.0605.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Ryan, Sarah, Eunice Lee, Hamisha Salih, Jenny Radcliffe, and Claudia DeGiovanni. "PS06 The beast beneath the blisters: assessment of depression and anxiety in patients with immunobullous disorders in a tertiary referral centre." British Journal of Dermatology 188, Supplement_4 (June 2023). http://dx.doi.org/10.1093/bjd/ljad113.358.

Full text
Abstract:
Abstract Immunobullous diseases can be disabling in the acute phase, causing widespread painful or pruritic skin and mucosal lesions. The subsequent psychological consequences of these disorders have not been fully evaluated. We treated a 53-year-old woman for severe bullous pemphigoid affecting her skin and oral mucosa. Following resolution of disease, she was left with debilitating anxiety and depression. This case prompted us to look at the psychological impact of immunobullous disease in our cohort. We used the Patient Health Questionnaire (PHQ-9), General Anxiety Disorder (GAD-7) and Dermatology Life Quality Index to establish the psychosocial impact in patients attending the immunobullous specialist clinic at a large tertiary dermatology centre. An assessment of pain using a numerical pain-rating scale and a question regarding any pre-existing mental health conditions were included. Twelve patients with various immunobullous conditions were surveyed. Seventy-five per cent (n = 9) of patients were identified as having a mood disorder via their PHQ-9 and GAD-7 scores. The PHQ-9 scores indicated mild (50%), moderate (17%) and severe (8%) depression symptoms in these patients. Twenty-five per cent and 17% of patients had a GAD-7 score indicating mild and moderate anxiety, respectively. Three patients declared that they had a previous mental health diagnosis; however, only mild depression and mild anxiety were identified in two of these patients. Only one of these patients volunteered mental health symptoms during their consultation, indicating an unrecognized burden of disease in this community. Our findings support previous research indicating high rates of depression in patients with immunobullous disease. Furthermore, there is an established association between bullous pemphigoid and neuropsychiatric conditions, with identification of autoantigen expression in the central nervous system. Mood disorders have a significant effect on patients’ experience of disease, and are likely to have an impact on disease course and engagement with treatment. A large European study found that dermatologists underestimate the severity of mood disorders. Therefore, the incorporation of validated measures for assessment of mood disorders such as PHQ-9 and GAD-7 into clinical practice is essential to identify the high proportion of patients with immunobullous disease suffering from these disorders. Quality of life measures, which are commonly assessed, are not sufficient for holistic management of these patients. These findings support the invaluable role of a psychologist within dermatology centres, and appropriate referrals to these services will improve with assessment during clinic consultations.
APA, Harvard, Vancouver, ISO, and other styles
30

Ahmad Lone, Shafkat, Haris Manzoor Qadri, and Shakil U Rehman. "COMPARISON OF THE RECOVERY RATE OF OTOMYCOSIS USING CLOTRIMAZOLE DROPS, CLOTRIMAZOLE CREAM AND 10% POVIDONE IODINE SOLUTION (BETADINE) IRRIGATION." INDIAN JOURNAL OF APPLIED RESEARCH, November 1, 2022, 18–20. http://dx.doi.org/10.36106/ijar/8100783.

Full text
Abstract:
Otomycosis is one of the common conditions encountered in ENT practice. Difference of opinion does exist regarding ideal treatment modality. Compare the efcacy of 1% clotrimazole drops, 1% cl Aim: otrimazole cream and 10% betadine irrigation in the treatment of otomycosis. Randomized control study conducted in the Method: department of ENT and Head and Neck surgery of Government Medical College Baramulla. The study was conducted on 80 patients over a period of 6 months, clinically diagnosed with otomycosis. Patients were randomly allotted to three groups. Improvement in symptoms of pruritis, pain and blocked sensation on 1st, 2nd, 3rd and 4th follow up visits was recorded. All patients were asked the opinion about preferred treatment modality. When compared the Results: symptoms on day one and subsequent follow ups, the change in symptoms in all the groups was signicant. Group 2 with 1% clotrimazole cream had signicant improvement on rst visit only. By 4th visit all the groups had signicant improvement.
APA, Harvard, Vancouver, ISO, and other styles
31

Nakamura, Yu, Kohei Narita, Rei Kim, Kenichi Nishiyama, Takashi Kikuchi, Ichiro Ishikawa, and Hiroshi Aoki. "Long-Term Safety, Tolerability, and Efficacy of a Transdermal Donepezil Patch in Patients with Severe Alzheimer’s Disease." Journal of Alzheimer's Disease, September 9, 2023, 1–9. http://dx.doi.org/10.3233/jad-230386.

Full text
Abstract:
Background: Oral formulations are not suitable for demented patients with dysphagia, those refuse to take tablets, or those with drug compliance problem. However, only oral formulations of donepezil hydrochloride are approved for the treatment of severe Alzheimer’s disease in Japan. Objective: To evaluate the safety, tolerability, and efficacy of long-term application of a 55.0 mg transdermal donepezil patch switched from a 10 mg oral donepezil hydrochloride tablet, for the treatment of patients with severe Alzheimer’s disease. Methods: A 52-week, multicenter, open-label, uncontrolled (phase III) study (jRCT2080224612) was conducted in Japan between April 2019 and August 2021. A 10 mg donepezil hydrochloride tablet was administered once a day for four weeks; a 55.0 mg donepezil patch was then applied once a day for 52 weeks in patients with severe Alzheimer’s disease. Results: Of 64 patients received the patch, 45 completed the 52-week period. The overall discontinuation rate was 29.7% (19/64). Among the 19 patients discontinued, six patients 9.4% (6/64) discontinued due to adverse events. The incidence of adverse events at application sites was 67.2% (43/64), including application site erythema 29.7% (19/64), application site pruritus 25.0% (16/64), and contact dermatitis 20.3% (13/64). Adverse events were mild and did not increase with time, demonstrating a favorable safety profile. Cognitive function, measured using the Mini-Mental State Examination, was maintained for up to 24 weeks. Conclusions: Adverse events were considered manageable in a clinical setting. The long-term application of a 55.0 mg donepezil patch once a day was feasible treatment in patients with severe Alzheimer’s disease.
APA, Harvard, Vancouver, ISO, and other styles
32

Nakamura, Yu, Takumi Omori, Rei Kim, Kenichi Nishiyama, Takashi Kikuchi, Ichiro Ishikawa, and Hiroshi Aoki. "Efficacy and Safety of a Transdermal Donepezil Patch in Patients with Mild to Moderate Alzheimer’s Disease: Open-Label, Extension Study." Journal of Alzheimer's Disease, June 14, 2023, 1–9. http://dx.doi.org/10.3233/jad-230387.

Full text
Abstract:
Background: In Japan, only oral formulation of donepezil hydrochloride is approved for the treatment of Alzheimer’s disease. Objective: To evaluate safety and efficacy of a donepezil patch 27.5 mg application for 52 weeks in patients with mild-to-moderate Alzheimer’s disease; and to evaluate safety on switching from donepezil hydrochloride tablets. Methods: This 28-week, open-label study (jRCT2080224517) is an extension of a 24-week double-blind (donepezil patch 27.5 mg versus donepezil hydrochloride tablet 5 mg) noninferiority study. The patch group (continuation group) continued administration of the patch and the tablet group (switch group) switched to the patch in this study. Results: A total of 301 patients participated (156 patients continued using patches; 145 patients switched). Both groups showed similar course on the Alzheimer’s Disease Assessment Scale-cognitive component-Japanese version (ADAS-Jcog) and ABC dementia scales. At weeks 36 and 52, changes in ADAS-Jcog from week 24 [mean (standard deviation)] were 1.4 (4.8) and 2.1 (4.9) in the continuation group, and 1.0 (4.2), and 1.6 (5.4) in the switch group. The incidence of adverse events at application site in the continuation group over 52 weeks was 56.6% (98/173). Erythema, pruritus, and contact dermatitis at application site were observed in more than 10 patients each. There was no additional adverse event of clinical concern, and no increase in their incidence from the double-blind study. During the four weeks following switching, no patient discontinued or suspended administration due to adverse events. Conclusion: Application of the patch for 52 weeks was well tolerated and feasible, including switching from tablets.
APA, Harvard, Vancouver, ISO, and other styles
33

Raj, Aravindh, and Harsha Patel. "EVALUATION OF INTRATHECAL DEXMEDETOMIDINE ADDED TO BUPIVACAINE FOR LABOR ANALGESIA." INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, March 1, 2023, 61–63. http://dx.doi.org/10.36106/ijsr/0715064.

Full text
Abstract:
Background And Aims: The aim of this study was to evaluate the effectiveness of intrathecal dexmedetomidine with bupivacaine for labor analgesia by assessment of onset, duration and quality of analgesia and neonatal outcomes. Method: In this study 40 eligible parturient who received dexmedetomidine 5 g and heavy bupivacaine 0.5% 2.5 mg diluted upto 2.5 cc with sterile NS intrathecally for labor analgesia were selected. The time of onset, duration and quality of analgesia were noted. Maternal parameters pulse rate, systolic blood pressure, motor block and side effects of pruritus, nausea, vomiting, hypotension and headache were recorded. Neonatal outcomes in terms of mode of delivery and APGAR score were noted. If VAS >3, analgesia was supplemented with epidural bupivacaine 0.125% 10 ml during labor. For rescue analgesia, Inj. Tramadol 1 – 2 mg/kg iv was given as per institutional protocol if the patient VAS score was still more than 3 even after second dose of epidural. Result: Mean time for onset of analgesia was 2 minutes (VAS<3). All parturient had VAS < 3 throughout the labor. Mean duration of Labor was 99.4 ± 48.35 min. Total duration of labor ranges from 45 minutes to 210 minutes in our study. Most 92.5% of parturient had maximum motor blockade of grade 1 and it was lasted maximum upto 30 min. Hypotension was observed in two parturient and one parturient had nausea, which responded to conservative management. The mean APGAR score at 1 min was 8.85 ± 0.97 and at 5 min it was 10 (excluding LSCS delivery). Out of 40 total, 30 parturient have graded labor analgesia as excellent and rest have graded as good. Conclusion: Dexmedetomidine (5μg) seems to be a safe and efcacious adjuvant to intrathecal bupivacaine 0.5% (2.5 mg) in women undergoing vaginal delivery. This may be helpful for parturient coming late to the delivery room, seeking rapid onset with good quality of analgesia
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography